7 news items
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
BNTX
GMAB
1 Jun 24
/lung-cancer.html. Accessed May 14, 2024.
ii Mayo
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
BNTX
GMAB
1 Jun 24
://www.cancer.org/cancer/types/lung-cancer.html. Accessed May 14, 2024
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
GMAB
23 May 24
for presentation have been published and may be accessed online via
Genmab Completes Acquisition of ProfoundBio
GMAB
21 May 24
or endometrioid platinum-resistant ovarian cancer.
In addition, the transaction provides Genmab with access
Genmab Completes Acquisition of ProfoundBio
GMAB
21 May 24
, the transaction provides Genmab with access to ProfoundBio's novel ADC technology platforms, which complement Genmab's already validated suite of proprietary
9vhrpuc m1g4u
GMAB
14 May 24
transformation (RT). All abstracts accepted for presentation have been published and may be accessed online via
7za49so9asd19t41c7d
GMAB
3 Apr 24
/register/BI9da0549848d848cdaa4b6cd96079bafd. Registered participants will receive an email with a link to access dial-in information
- Prev
- 1
- Next